Ibogaine Treatment Raleigh, NC: Law, Cost, Clinics

Ibogaine Treatment Raleigh, North Carolina: Where the Law Stands and What You Can Actually Do

North Carolina has a bill that would fund ibogaine research — and it names ibogaine explicitly, which most state psychedelic bills do not. It has also been sitting in a Senate appropriations committee since 5 May 2026 with no recorded vote. Both of those things are true at once, and if you are in Raleigh trying to work out your options, the gap between them is the whole story.

Ibogaine remains Schedule I under federal law. There is no licensed ibogaine clinic in North Carolina, and nothing currently before the General Assembly would create one. For Raleigh and Wake County patients who need treatment now, the legal route is a medically supervised clinic in Mexico.

Psychedelic Connect is a treatment advisory service. We help Triangle patients decide whether ibogaine is reasonable in their case and, where it is, connect them with vetted clinics. Call (866) 435-7057 or request a consultation to speak with a patient coordinator.

Before planning anything, see what ibogaine treatment costs.

Can You Get Ibogaine Treatment in Raleigh?

No. Ibogaine is a Schedule I controlled substance under federal law and North Carolina has created no exemption. No clinic in Raleigh, Durham, Chapel Hill or anywhere in the state can legally administer it. Legal, medically supervised treatment means travelling abroad.

If a North Carolina provider advertises ibogaine, treat it as a red flag rather than a shortcut. Ibogaine affects cardiac rhythm, and the deaths associated with it have overwhelmingly happened outside medical settings where nobody screened the patient or monitored the heart.

What Is North Carolina’s HEAL Act, and Does It Cover Ibogaine?

Senate Bill 1018 — the HEAL Act — would appropriate $5.4 million for state-funded research into psychedelic therapies, and its text names ibogaine alongside MDMA and psilocybin. It has not passed. It has not received a floor vote.

That explicit naming matters. Most state psychedelic legislation funds MDMA and psilocybin, the two compounds holding FDA Breakthrough Therapy designation, and leaves ibogaine out. The HEAL Act requires a grant recipient to attest that funds will be used for research “on the use of psychedelic drugs, including ibogaine, MDMA, and psilocybin.” Ibogaine is named first.

What the bill would do, from the filed text:

• $5.4 million in nonrecurring funds from the General Fund for the 2026–27 fiscal year, to the Department of Health and Human Services’ Division of Mental Health, Developmental Disabilities, and Substance Use Services.
• Creates a Breakthrough Therapies Research (BTR) Grant Fund awarding competitive grants of no less than $1 million each, to be announced no later than 1 July 2027, funding three years of research.
• All research must be conducted in North Carolina, and applicants are limited to federal medical or research entities and academic institutions located in the state. Participants must be 21 or older.
• Research must focus on populations disproportionately affected by trauma: military veterans, first responders, frontline healthcare personnel, and survivors of domestic violence or sexual assault.
• Creates a Breakthrough Therapies Task Force, to be appointed no later than 1 December 2026, including faculty from the UNC School of Medicine and ECU’s Brody School of Medicine, and two members representing Native communities — one chosen by the Eastern Band of Cherokee Indians and one by the Lumbee Tribe of North Carolina.
• Every funded study must measure participants’ baseline pain levels and any change in them — an unusual requirement, and a sensible one.

One drafting detail worth knowing if you follow this bill: Section 1(a) describes “two competitive BTR Grants,” while Section 1(c) authorises “up to five.” The filed edition says both. It is the kind of inconsistency that normally gets cleaned up in committee — which is one more reason the bill’s current parking spot matters.

Source: North Carolina General Assembly, Senate Bill 1018 (2025–2026 Session), Edition 1 as filed. Accessed 12 September 2026.

Has the HEAL Act Passed?

No. It was filed on 4 May 2026, referred to Senate Rules, withdrawn from that committee and re-referred to Appropriations/Base Budget on 5 May 2026 — and the legislative record shows no action since. There are no recorded votes.

The full history on file with the General Assembly is three lines long:

• 4 May 2026 — filed by Senators Chitlik and Brinson; referred to the Committee on Rules and Operations of the Senate.
• 5 May 2026 — withdrawn from committee.
• 5 May 2026 — re-referred to the Committee on Appropriations/Base Budget.

A bill sitting in an appropriations committee with no scheduled hearing is not a bill about to become law. It may be revived, and its language could be folded into a budget bill — that happens routinely in Raleigh. But nobody can honestly tell you when, and nobody can enrol you in a study that has not been funded, designed or approved. If someone points at the HEAL Act as a reason to wait, ask them for the committee calendar.

Source: North Carolina General Assembly bill history for S1018. Accessed 12 September 2026.

Would Raleigh See That Research Money?

Probably, if it ever passes. The bill restricts grants to academic and federal research institutions located in North Carolina, and the Research Triangle holds most of them. That is a reason to watch, not a reason to wait.

UNC School of Medicine in Chapel Hill and Duke in Durham sit within half an hour of downtown Raleigh, and UNC faculty are written into the task force by name of institution. If the HEAL Act is funded, the Triangle is the most likely place for the work to land.

That would still be a clinical trial: narrow eligibility criteria, a specific diagnosis, a screening process most applicants do not pass, and — by the bill’s own timetable — grants announced no later than July 2027 for studies running three years. Someone in active dependence today cannot plan around that.

How Bad Is the Overdose Problem in Wake County?

Less severe than most of North Carolina, and that is worth saying plainly. Wake County’s overdose death rate runs well below the statewide rate — but 233 people still died in 2023, and a lower rate is no comfort if you are one of the families counting.

From the NC Division of Public Health’s county overdose data for 2017–2021:

• Wake County’s medication and drug overdose death rate was 15.5 per 100,000 residents, against a statewide rate of 27.6.
• The opioid overdose death rate was 12.8 per 100,000 in Wake, against 22.7 statewide.
• Opioid prescribing was also lower: 11.7 Wake residents per 100 received opioid pills in 2021, against 13.0 statewide.

Wake County Health and Human Services’ own 2024 epidemiologic profile records more than 1,800 overdose deaths in Wake County between 2010 and 2023, with the annual count easing slightly from 241 in 2022 to 233 in 2023.

We include the favourable comparison because leaving it out would be dishonest, and because it changes the advice. Wake County has comparatively good treatment infrastructure and comparatively low prescribing. If you are here and conventional treatment has not worked, that is usually a fact about your situation rather than about local services — and it is worth exhausting what is available before travelling abroad for a Schedule I drug.

Sources: NCDHHS Division of Public Health, Wake County Overdose Slides (rates for 2017–2021); Wake County Health and Human Services, 2024 Wake County Drug Overdose Integrated Epidemiologic Profile (2025).

What Is in the Triangle’s Drug Supply Right Now?

Fentanyl, and increasingly nitazenes — a class of synthetic opioids never approved for medical use that has moved from the Midwest into the southeast. If you are using while you plan treatment, free anonymous drug checking is available locally.

Wake County’s 2024 profile flags isotonitazene (“ISO”) as an emerging substance in the supply. It binds the same receptor as fentanyl, carries the same overdose risk, and responds to naloxone.

The useful local detail: the UNC Street Drug Analysis Lab at Chapel Hill tests drug samples free and anonymously, and supplies test kits to organisations. For someone in the Triangle waiting on a treatment decision — and a decision about ibogaine takes weeks, not days — knowing what is actually in the supply is not an abstraction. Keep naloxone within reach, and do not use alone.

We say this because the honest version of our advice is that ibogaine is a considered, prepared, screened decision. Staying alive long enough to make it is the prerequisite.

Does Ibogaine Fit What You Are Treating?

It depends heavily on the substance. Ibogaine’s strongest evidence is in opioid dependence, where it can interrupt withdrawal. For stimulants the evidence is far thinner, and for most other presentations it is anecdotal.

• Opioid dependence — fentanyl, heroin, prescription opioids, methadone and buprenorphine. This is where the published work is. See ibogaine for opioid dependence.
• Stimulants — there is no stimulant withdrawal syndrome for ibogaine to interrupt in the way it interrupts opioid withdrawal. See ibogaine and methamphetamine.
• Trauma and PTSD — the population the HEAL Act was written around. Several clinics run protocols built for combat-related PTSD and traumatic brain injury. See ibogaine for veterans.

The published evidence for opioid dependence is promising but limited: mostly observational studies with small numbers and no control group. That is precisely why states are trying to fund trials, and it is why we will not tell you the question is settled.

What Happens Before You Travel?

Screening comes first. Ibogaine affects heart rhythm, so clinics require an ECG and bloodwork, a full medication review and a medical history before accepting anyone. Some people are screened out — and being told no is the system working.

• Initial conversation — what you are treating, what you have already tried, current medications and doses.
• Medical screening — ECG, liver and kidney panels, electrolytes. Some medications, particularly certain antidepressants and long-acting opioids, need a supervised taper arranged well beforehand.
• Clinic matching — facilities whose medical model fits the presentation, not whichever one has a bed free.
• Treatment — most programmes run seven to ten days.
• Integration — the part that decides whether the result holds. See integration therapy after ibogaine.

If you are in acute withdrawal or crisis right now, call 988 or 911. Ibogaine requires weeks of preparation and cannot be accessed on an emergency timeline.

Getting from Raleigh to a Mexican Clinic

Raleigh–Durham International connects to Mexico mainly through Atlanta, Charlotte, Dallas–Fort Worth or Houston rather than directly, so most Triangle patients fly one leg to a hub and one leg on. Cancún holds the largest concentration of established ibogaine clinics and is generally the more straightforward connection from the east coast; Baja California clinics near Tijuana and Rosarito are usually reached via San Diego. Schedules shift seasonally, so we check current routing with you rather than printing a flight time that goes stale.

Travel logistics are the least important variable here. Programme length, whether a physician is on site overnight, what screening is required before you fly, and whether integration is included matter far more to the outcome.

What Does Treatment Cost for North Carolina Patients?

Between $5,000 and $15,000, depending on length of stay and facility. Insurance does not cover it, because ibogaine is Schedule I in the United States. Budget separately for flights and for integration support afterwards.

The range reflects real differences: programme length, whether a physician is on site around the clock, the level of cardiac monitoring, private versus shared accommodation, and whether integration is bundled. A price well below that range usually means fewer medical staff, which is the wrong place to economise on a drug with known cardiac risk.

Nothing in the HEAL Act would change this for private patients. A state-funded study does not bill participants — but it also does not exist yet.

What Psychedelic Connect Does

We are a treatment advisory service, not a clinic. We do not administer ibogaine and we do not own a facility. We help you work out whether ibogaine is reasonable in your specific case, and if it is, which clinic fits.

We visit the clinics we recommend — we look at medical staffing, monitoring equipment, what happens overnight, and what a facility does when something goes wrong. We are guided by people who get it, including clinicians and people who have been through this themselves. Our clinical content is reviewed by Christopher Diviaio, LCSW. If you want to pressure-test any provider, including us, our guide on how to vet an ibogaine provider lists the questions worth asking.

Resources in Raleigh and Wake County:

• SAMHSA National Helpline: (800) 662-4357 — 24/7 treatment referral (samhsa.gov)
• 988 Suicide & Crisis Lifeline: call or text 988
• Veterans Crisis Line: 988, then Press 1
• Wake County Drug Overdose Prevention Coalition — local prevention, naloxone distribution and education (wake.gov)

Consultation — Call Today

If you are in Raleigh, Cary, Durham, Chapel Hill, Apex, Wake Forest or anywhere in the Triangle, call (866) 435-7057 to talk with a patient coordinator. You can also start with our online form and we will follow up within one business day.

Medical Disclaimer: Psychedelic Connect is a treatment advisory service. We do not provide medical advice. Ibogaine treatment involves serious medical considerations including cardiac risks. Always consult a qualified medical professional before pursuing any treatment.

Frequently Asked Questions — Ibogaine Treatment, Raleigh and North Carolina

Is ibogaine legal in North Carolina?
No. Ibogaine is a Schedule I controlled substance under federal law and North Carolina has not created a state exemption. No clinic in the state can administer it. Senate Bill 1018, the HEAL Act, would fund research that includes ibogaine, but it has not passed and would not create a treatment pathway outside a study.

What is the status of North Carolina’s HEAL Act?
It was filed on 4 May 2026 and re-referred to the Senate Appropriations/Base Budget committee on 5 May 2026. The General Assembly’s record shows no action and no votes since. Its language could still be added to a budget bill, which is common practice, but as of September 2026 it is not law and no funding has been released.

Does North Carolina’s bill actually mention ibogaine?
Yes, and that is unusual. The filed text requires grant recipients to attest that funds will be used for research “on the use of psychedelic drugs, including ibogaine, MDMA, and psilocybin.” Most state psychedelic legislation covers only MDMA and psilocybin, the compounds with FDA Breakthrough Therapy designation.

How many people die of overdose in Wake County?
Wake County Health and Human Services recorded 233 overdose deaths in 2023, down slightly from 241 in 2022, and more than 1,800 between 2010 and 2023. Wake’s rate runs below the state’s: 15.5 per 100,000 against 27.6 statewide for 2017–2021, with opioid-specific rates of 12.8 against 22.7.

Can I get drugs tested in the Triangle?
Yes. The UNC Street Drug Analysis Lab at Chapel Hill tests samples free and anonymously and provides test kits to organisations. Wake County’s 2024 overdose profile flags nitazenes — synthetic opioids never approved for medical use — as an emerging presence in the supply alongside fentanyl. Both respond to naloxone.

How dangerous is ibogaine?
It carries real cardiac risk, which is why legitimate clinics require an ECG and bloodwork beforehand and why a facility without a physician on site should be ruled out. The published evidence for opioid dependence is promising but limited — mostly observational studies with small numbers and no control group. Anyone telling you the risk is negligible, or that the evidence is settled, is overselling it.

Psychedelic Connect · (866) 435-7057 · contact@psychedelic-connect.com

Published 12 September 2026 · Last updated 12 September 2026 · Clinical review: Christopher Diviaio, LCSW